
PTC Therapeutics (NASDAQ:PTCT) expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug’s strong first year of sales can be sustained.
Speaking at the Jefferies Healthcare Conference in London, CEO Matt Klein said the company continues to see Sephience as a potential $2 billion-plus opportunity, though he stressed that figure is not official guidance and would take time to reach.
“We’re not going to guide to $2 billion next year,” Klein said, adding that the company expects steady U.S. growth and that its forthcoming guidance will reflect what it believes it can achieve.
Klein said PTC closed the third quarter with $182 million in revenue and more than $2.1 billion in cash. The company remains on track for its goal of reaching cash flow break-even in 2026, he said, positioning it to pursue sustainable profitability in 2027.
Launch Reaches More Than 2,000 Patients
About a year into the Sephience launch, more than 2,000 patients globally were on the drug, Klein said. PTC has launched it in the U.S., Europe and Japan and expects it to be available in more than 20 countries by year-end.
The company estimates that 17,000 people in the U.S. and 58,000 across the U.S. and other countries where it believes it can obtain access represent the potential patient population. Klein estimated that 14,000 to 15,000 U.S. patients had not yet tried Sephience.
Early in the launch, roughly two-thirds of patients had previously tried and failed another therapy, while approximately 20% to 25% were therapy-naive, Klein said. He estimated that 2,000 to 2,500 patients remained on Kuvan, another oral treatment, leaving room for additional switches.
Klein said PTC had received prescriptions from all U.S. centers of excellence by the second full quarter of the launch. He also pointed to social media and patient networks as ways people who were not regularly visiting clinics learned about the drug.
Jefferies analyst Faisal Khurshid asked whether the initial pace could be maintained. Klein acknowledged that prescribing can fluctuate around summer holidays and year-end closures but said the company expects continued U.S. growth.
International Access and Competition
Outside the U.S., Klein said PTC expects revenue in the fourth quarter to be roughly steady with the third quarter as it awaits access to additional markets. He expects new-market growth to come in 2027, although reimbursement discussions in Europe will take time.
Japan has had a strong start, Klein said. He expects another potential inflection after the first year following approval, when the required prescription renewal period expands beyond a month.
Asked about a kidney-directed therapy being developed by Otsuka, Klein said he had heard that potential approval could come in 2028 or later. He described the approach as potentially complementary to Sephience, while saying there was still more to learn about it.
Deal Strategy
CFO Pierre Gravier said PTC is looking for disciplined business-development opportunities that could use its global commercial infrastructure and accelerate growth. He said the company does not need to pursue deals simply to deploy capital.
Gravier described the agreement for Fabry disease gene therapy ST-920, which involved a $100 million upfront payment, as a distinctive opportunity rather than a sign that PTC plans to increase spending on early-stage gene therapy assets. Klein said the potential durability of the treatment and the cost of existing enzyme replacement therapy could support its commercial value.
About PTC Therapeutics (NASDAQ:PTCT)
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
